ICM
VIR icon

Infini Capital Management’s Vir Biotechnology VIR Stock Holding History

Infini Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$24K – 56
2021
Q2 		$24K Buy
+500
New +$22.7K 0.03% 45

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Infini Capital Management's VIR Position: Q3 2021 in Review

Infini Capital Management sold out of Vir Biotechnology (VIR) in Q3 2021, closing a stake of 500 shares — an estimated $24K sold.

Infini Capital Management first reported a position in VIR in Q2 2021 and held it in 1 quarter. The position peaked at $24K in Q2 2021. 175 funds tracked by Wall St. Rank hold VIR as of Q3 2021.

  • Infini Capital Management reported no remaining Vir Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Infini Capital Management sold 500 Vir Biotechnology shares in Q3 2021, an estimated $24K.
  • Infini Capital Management first reported a position in Vir Biotechnology in Q2 2021 and held it in 1 quarter.
  • Infini Capital Management's Vir Biotechnology position peaked at $24K in Q2 2021.
  • 175 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2021.

Based on Infini Capital Management's 13F filing for Q3 2021, filed 7 Nov 2022.